Prices are updated after-hours

Mitsui Chemicals Inc

MITUY | News | $14.65 -19.3% 110

(0.0% 1d) (-3.9% 1m) (15.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-90.74% volume)
Earnings Calendar:
Market Cap: $ 5,884,723,780
https://www.mitsuichem.com/
Sec Filling | Patents | n/a employees

(JP)

add to watch list Paper trade email alert is off

Persimmon

PSMMF | $16.23 1.82% 4.7K

Consumer Durables

(0.0% 1d) (4.0% 1m) (-4.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (843.2% volume)
Earnings Calendar:
Market Cap: $ 5,188,527,200
http://persimmonhomes.com
Sec Filling | Patents | n/a employees

(GB) Persimmon Plc operates as a holding company of the Persimmon Group of companies. It engages in building, designing, and construction of new homes. The company was founded by Duncan Henry Davidson in 1972 and is headquartered in Fulford, the United Kingdom.

msa construction

add to watch list Paper trade email alert is off

SEIKO EPSON CORP

SEKEF | $14.2 -1.18% 1.8% 0

Electronic Technology

(0.0% 1d) (0.0% 1m) (-3.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (0.0% volume)
Earnings Calendar:
Market Cap: $ 5,467,316,348
http://www.epson.jp
Sec Filling | Patents | n/a employees

(JP) Seiko Epson Corp. engages in the development, manufacture, and sale of information equipment. It operates through the following business segments: Printing Solutions, Visual Communications, and Wearable & Industrial Products. The Printing Solutions segment offers Inkjet printers, serial impact dot matrix printers, page printers, color image scanners, large-format inkjet printers, industrial inkjet printing systems, printers for use in POS systems, label printers and related consumables, office papermaking systems, personal computers and others. The Visual Communications segment offers 3LCD projectors, HTPS-TFT panels for 3LCD projectors, smart eyewear and others. The Wearable & Industrial Products segment offers watches, watch movements, sensing equipment, industrial robots, IC handlers, crystal units, crystal oscillators, quartz sensors, CMOS LSIs, metal powders, surface finishing and others. The company was founded on May 18, 1942 and is headquartered in Suwa, Japan.

communication computational sensor

add to watch list Paper trade email alert is off

Mitsui Chemicals Inc

MITUF | News | $28.02 -32.91% 100

Process Industries

(0.0% 1m) (3.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-50.0% volume)
Earnings Calendar:
Market Cap: $ 5,627,643,696
http://www.mitsuichem.com
Sec Filling | Patents | n/a employees

(JP) Mitsui Chemicals, Inc. manufactures and sells petrochemicals and industrial inorganic chemical products. It operates through the following segments: Mobility, Healthcare, Food and Packaging, Base Material, and Others. The Mobility segment covers the new product development support business (solution business) for elastomers, functional compounds, functional polymers, polypropylene compounds, automobiles and other industrial products. The Healthcare segment includes vision care material, non-woven fabric, dental material, and personal care material. The Food and Packaging segment handles the coating and functional materials, functional films and sheets, and agricultural chemicals. The Base Material segment covers the ethylene, propylene, polyethylene, polypropylene, catalysts, phenols, high-purity terephthalic acid, PET resins, polyurethane materials, and industrial chemicals. The Others segment comprises of other related businesses. The company was founded on July 1, 1955 and is headquartered in Tokyo, Japan.

agricultural agriculture pets

add to watch list Paper trade email alert is off

Innate Pharma SA

IPHYF | $2.65 104.6% 300

Health Technology

(0.0% 1d) (13.2% 1m) (-10.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-62.5% volume)
Earnings Calendar:
Market Cap: $ 204,779,375
http://www.innate-pharma.com/en
Sec Filling | Patents | n/a employees

(FR) Innate Pharma SA is a biopharmaceutical company. It focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.

cancer immunotherapy antibody t-cell treatment ceiling cancer treatments

add to watch list Paper trade email alert is off

Mallinckrodt plc

MNKKQ | $0.02

Manufacturing

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (10.5% 3d) (0.0% 7d) (-51.93% volume)
Earnings Calendar:
Market Cap:
http://www.mallinckrodt.com/
Sec Filling | Patents | 3085 employees

(IE) Mallinckrodt Pharmaceuticals is an Irish–tax registered manufacturer of specialty pharmaceuticals , generic drugs and imaging agents. In 2017 it generated 90% of sales from the U.S. healthcare system. While Mallinckrodt is headquartered in Ireland for tax purposes, its operational headquarters are in the U.S. Mallinckrodt's 2013 tax inversion to Ireland drew controversy when it was shown Acthar, was Medicaid's most expensive drug. Mallinckrodt acquires , manufactures, and distributes products used in diagnostic procedures and in the treatment of pain and related conditions. This includes the acquisition, manufacture, and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products, and radiopharmaceuticals. The company employed 5,500 and had net sales of $3.2 billion in 2017; of which $2.9 billion was from the U.S. healthcare system.

diagnostics acquisitions treatment

add to watch list Paper trade email alert is off

Veritiv Corporation

VRTV | $169.99 0.0% 1.2M

Distribution Services

(0.0% 1d) (0.0% 1m) (37.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (470.28% volume)
Earnings Calendar:
Market Cap: $ 2,306,307,027
http://www.veritivcorp.com
Sec Filling | Patents | 8000 employees

Veritiv Corp. engages in business-to-business distributor of print, publishing, packaging, facility solutions, print and publishing products and services. The company provides logistics and supply chain management solutions to its customers. It operates through the following segments: Print, Publishing, Packaging and Facility Solutions. The Print segment sells and distributes commercial printing, writing, copying, digital, wide format and specialty paper products, graphics consumables and graphics equipment primarily in the U.S., Canada and Mexico. This segment also includes customized paper conversion services of commercial printing paper for distribution to document centers and form printers. The Publishing segment sells and distributes coated and uncoated commercial printing papers to publishers, retailers, converters, printers and specialty businesses for use in magazines, catalogs, books, directories, gaming, couponing, retail inserts and direct mail. This segment also provides print management, procurement and supply chain management solutions to simplify paper and print procurement processes for the customers. The Packaging segment provides standard as well as custom and comprehensive packaging solutions for customers based in North America and in key global markets. The Facility Solutions segment sources and sells cleaning, break-room and other supplies such as towels, tissues, wipers and dispensers, can liners, commercial cleaning chemicals, soaps and sanitizers, sanitary maintenance supplies and equipment, safety and hazard supplies, and shampoos and amenities primarily in the U.S., Canada and Mexico. The company was founded in July 10, 2013 and is headquartered in Atlanta, GA.

games

add to watch list Paper trade email alert is off

Mallinckrodt plc

MNK | $0.3402 -0.06% 540K

n/a

(0.0% 1d) (1.8% 1m) (-93.0% 1y) (0.0% 2d) (-16.6% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 4,520,979
http://mallinckrodt.com
Sec Filling | Patents | 3400 employees

(IE) Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

brands

add to watch list Paper trade email alert is off

Mallinckrodt plc

MNKPF | $17.25

n/a

(0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (186.25% volume)
Earnings Calendar:
Market Cap: $ 0
http://www.mallinckrodt.com/
Sec Filling | Patents | 3085 employees

(IE)

add to watch list Paper trade email alert is off

Mallinckrodt plc

MNKTQ | $0.12 -66.67% 39K

Manufacturing

(0.0% 1d) (0.0% 1m) (-36.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-97.94% volume)
Earnings Calendar:
Market Cap: $ 1,594,702
http://www.mallinckrodt.com/
Sec Filling | Patents | 3046 employees

(IE) mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit

add to watch list Paper trade email alert is off

ATLAS COPCO AB

ATLFF | News | $14.785 -39.21% 3.3K

Manufacturing

(0.0% 1d) (-1.8% 1m) (34.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-98.41% volume)
Earnings Calendar:
Market Cap: $ 23,077,552,133
https://www.atlascopco.com/
Sec Filling | Patents | n/a employees

(SE)

add to watch list Paper trade email alert is off

Endo International plc

ENDP | $0.2926 -9.6%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-5.0% 3d) (0.0% 7d) (97.63% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 68,802,809
http://www.endo.com
Sec Filling | Patents | 3172 employees

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.

cardiovascular women health nervous system women brands msa injection

add to watch list Paper trade email alert is off

NanoString Technologies, Inc.

NSTG | $0.1053 -37.43% -0.19% 0

Health Technology

(0.0% 1d) (0.0% 1m) (-99.0% 1y) (0.0% 2d) (0.0% 3d) (-37.4% 7d) (-60.48% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 5,066,858
http://www.nanostring.com
Sec Filling | Patents | 551 employees

(US) NanoString Technologies, Inc. engages in the development and commercialization of instrument and services for profiling of genes and proteins from tissue sample. It offers GeoMx Digital Spatial Profiler, nCounter Systems, analysis solutions, gene expression panels, Vantage 3D Assays, miRNA Assays, custom solutions, and Sample Prep and nCounter Consumables. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June 20, 2003 and is headquartered in Seattle, WA.

3d profitable

add to watch list Paper trade email alert is off

Restaurant Brands International Inc.

QSR | News | $71.32 -0.06% 180K

Consumer Services

(0.0% 1d) (-12.3% 1m) (2.7% 1y) (0.0% 2d) (-0.3% 3d) (-1.0% 7d) (NaN% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 22,564,395,549
http://www.rbi.com
Sec Filling | Patents | 6300 employees

(CA) Restaurant Brands International, Inc. is a holding company, which engages in the operation of quick service restaurants. It operates through the following segments: Tim Hortons, Burger King, and Popeyes. The Tim Hortons segment provides donut, coffee, and tea restaurant services. The Burger King segment manages fast food hamburger restaurant. The Popeyes segment handles chicken category of the quick service segment of the restaurant industry. The company was founded on August 25, 2014 and is headquartered in Toronto, Canada.

restaurant food brands

add to watch list Paper trade email alert is off

Discover Financial Services

DFS | $124.19 -0.06% 340K

Finance

(0.0% 1d) (-4.9% 1m) (13.7% 1y) (0.0% 2d) (0.0% 3d) (-1.4% 7d) (26.02% volume)
Earnings Calendar: 2024-01-17
Market Cap: $ 31,117,650,460
http://www.discoverfinancial.com
Sec Filling | Patents | 17200 employees

(US) Discover Financial Services is a holding company, which engages in the provision of direct banking and payment services. It operates through the Direct Banking and Payment Services segments. The Direct Banking segment offers Discover-branded credit cards issued to individuals and small businesses on the Discover Network; and consumer banking products and services, including private student loans, personal loans, home equity loans, and deposit products. The Payment Services segment includes PULSE, Diners Club, and the company's network partners business, which includes credit, debit, and prepaid cards issued on the Discover Network by third parties. The company was founded in 1986 and is headquartered in Riverwoods, IL.

brands payment

add to watch list Paper trade email alert is off

Ardelyx, Inc.

ARDX | News | $6.445 0.08% 890K

Health Technology

(0.0% 1d) (-17.4% 1m) (34.7% 1y) (0.0% 2d) (-4.3% 3d) (-5.3% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 1,499,661,322
http://www.ardelyx.com
Sec Filling | Patents | 88 employees

(US) Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

treatment

Drugs

IBSRELA (tenapanor hydrochloride)

add to watch list Paper trade email alert is off

Beam Global

BEEM | $6.315 -1.33% 38K

Utilities

(0.0% 1d) (-22.6% 1m) (-45.1% 1y) (0.0% 2d) (0.0% 3d) (4.2% 7d) (-25.86% volume)
Earnings Calendar: 2024-04-16
Market Cap: $ 91,177,675
http://beamforall.com
Sec Filling | Patents | 35 employees

Beam Global engages in the invention, design, engineering, manufacture, and sale of solar powered products. It offers solar powered products and proprietary technology solutions for electric vehicle charging infrastructure, out of home advertising platforms, and energy security and disaster preparedness. The company was founded by Robert Lane Noble on June 12, 2006 and is headquartered in San Diego, CA.

energy vehicles solar eletric vehicle security electric vehicles eletrical

add to watch list Paper trade email alert is off

TE Connectivity Ltd.

TEL | News | $140.44 -0.03% 490K

Electronic Technology

(0.0% 1d) (0.4% 1m) (11.2% 1y) (0.0% 2d) (0.3% 3d) (-0.1% 7d) (-100.0% volume)
Earnings Calendar: 2024-01-24
Market Cap: $ 43,648,752,000
http://www.teconnectivity.com
Sec Filling | Patents | 82000 employees

(CH) TE Connectivity Ltd. engages in the design and manufacture of connectivity and sensors solutions. It operates through the following segments: Transportation, Industrial, and Communications Solutions. The Transportation Solutions segment offers products that are used in the automotive, commercial transportation, and sensors markets. The Industrial Solutions segment provides products that connect and distribute power, data, and signal. The Communications Solutions segment supplies electronic components for the data and devices and appliances markets. The company was founded in 2000 and is headquartered in Schaffhausen, Switzerland.

electronics automotive communication sensor

add to watch list Paper trade email alert is off

Genmab A/S

GMAB | $28.67 1.2% 41K

Health Technology

(0.0% 1d) (-3.1% 1m) (-29.9% 1y) (0.0% 2d) (0.0% 3d) (-3.1% 7d) (4.74% volume)
Earnings Calendar:
Market Cap: $ 18,957,453,779
http://www.genmab.com
Sec Filling | Patents | 548 employees

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

eye diseases cancer eye antibody leukemia treatment

add to watch list Paper trade email alert is off

ARCA biopharma, Inc.

ABIO | $3.41 4.92% 280K

Health Technology

(0.0% 1d) (83.4% 1m) (62.3% 1y) (0.0% 2d) (0.0% 3d) (0.9% 7d) (-67.77% volume)
Earnings Calendar:
Market Cap: $ 49,448,898
http://www.arcabiopharma.com
Sec Filling | Patents | 13 employees

(US) ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

cardiovascular heart genetic treatment

add to watch list Paper trade email alert is off